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Focal adhesion kinase contributes to proliferative
potential of ErbB2 mammary tumour cells but is
dispensable for ErbB2 mammary tumour
induction in vivo
Hicham Lahlou1, Virginie Sanguin-Gendreau1, Margaret C Frame3 and William J Muller1,2*
Abstract
Introduction: Activation of focal adhesion kinase (FAK) is hypothesized to play an important role in the
pathogenesis of human breast cancer.
Methods: To directly evaluate the role of FAK in mammary tumour progression, we have used a conditional FAK
mouse model and mouse mammary tumour virus (MMTV)-driven Cre recombinase strain to inactivate FAK in the
mammary epithelium of a transgenic mouse model of ErbB2 breast cancer.
Results: Although mammary epithelial disruption of FAK in this model resulted in both a delay in onset and a
decrease in the number of neoplastic lesions, mammary tumours occurred in 100% of virgin female mice. All of
the tumours and derived metastases that developed were proficient for FAK due to the absence of Cre
recombinase expression. The hyperplastic epithelia where Cre-mediated recombination of FAK could be detected
exhibited a profound proliferative defect. Consistent with these observations, disruption of FAK in established
tumour cells resulted in reduced tumour growth that was associated with impaired proliferation. To avoid the
selection for FAK-proficient ErbB2 tumour epithelia through escape of Cre-mediated recombination, we next
intercrossed the FAK conditional mice with a separate MMTV-driven ErbB2 strain that co-expressed ErbB2 and Cre
recombinase on the same transcriptional unit.
Conclusions: While a delay in tumour induction was noted, FAK-deficient tumours arose in 100% of female
animals indicating that FAK is dispensable for ErbB2 tumour initiation. In addition, the FAK-null ErbB2 tumours
retained their metastatic potential. We further demonstrated that the FAK-related Pyk2 kinase is still expressed in
these tumours and is associated with its downstream regulator p130Cas. These observations indicate that Pyk2 can
functionally substitute for FAK in ErbB2 mammary tumour progression.
Introduction
Elevated expression of FAK has been associated with
highly invasive human breast cancers [1,2]. In particular,
several groups have reported a correlation between FAK
and human epithelial growth factor receptor (ErbB2,
Neu) overexpression in ErbB2-positive human breast
cancer [3-5]. Activation of FAK has also been observed
in human breast cancer cell lines expressing elevated
levels of ErbB2 [6,7]. Moreover, recent studies have indi-
cated that FAK and the related kinase Pyk2 are
expressed in ErbB2-positive breast cancer and contri-
bute to the proliferative and invasive potential of breast
cancer cell lines [8,9].
Direct evidence for the in vivo importance of FAK in
tumourigenesis derives from several recent studies in
which components of the integrin signaling pathway
were selectively ablated in the germline of mice. For
example, mice heterozygous for a FAK null allele exhibit
a dramatic delay in tumour induction in a chemically-
induced skin carcinogenesis model [10]. Because
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The No. 4 inguinal mammary glands were used for
germline deletion of FAK results in embryonic lethality
[10,11], it is difficult to assess whether complete ablation
of FAK could impact on chemical skin carcinogenesis.
To circumvent this limitation, the same group demon-
strated that conditional ablation of FAK in the skin
resulted in an absolute block in the progression of
benign papilloma lesions to malignant carcinomas in
this model [12]. More recently, it has been shown that
prostate-specific ablation of FAK in an SV40 T antigen
mouse model resulted in the inability of prostate
tumours to progress to the aggressive neuroendocrine
phenotype [13].
Although these studies have largely focused on tissues
such as skin, there is compelling evidence suggesting that
activation of FAK is directly involved in the induction of
mammary tumours in vivo. In the polyomavirus middle
T (PyVmT) model of mammary tumour progression,
mammary epithelial disruption of FAK prevented the
transition of mammary hyperplastic growths into mam-
mary adenocarcinomas [14]. This result was subsequently
confirmed by a number of independent laboratories
[15-17]. By contrast, another group claimed that FAK
function in PyVmT tumour progression played a critical
role in the initial progression of primary epithelium to
the hyperplastic state [17]. The minor difference between
these groups likely reflects the timing at which FAK-defi-
cient lesions were monitored. Another suggested expla-
nation is that the block in PyVmT tumour progression
incurred by abrogation of FAK signaling was due to a
deficit in the tumour-initiating cell population [15].
Taken together, these observations confirm that FAK
plays a critical role in converting PyVmT mammary
epithelial hyperplasias into the malignant phenotype.
Given the dramatic impact of FAK deletion on PyVmT
tumour induction, we evaluated whether deletion of FAK
in an activated ErbB2 mouse model resulted in a compar-
able phenotype. To accomplish this, we first intercrossed
the mouse mammary tumour virus (MMTV)-activated
ErbB2 strain (NDL2-5) to separate strains of mice bearing
the MMTV-Cre and conditional FAK alleles and moni-
tored virgin female cohorts for the development of mam-
mary tumours. Although a delay in mammary tumour
onset was observed, all animals developed mammary
tumours that were highly metastatic. Genetic and bio-
chemical analyses revealed that the majority of these
tumours had escaped Cre-mediated recombination of the
conditional FAK alleles and were proficient for FAK
expression, indicating a strong selection for retention of
FAK signaling. Cre-mediated deletion of FAK in estab-
lished ErbB2 mammary tumour cells resulted in a pro-
found delay in tumour growth that was further associated
with a proliferative defect. Finally, using a transgenic
mouse model that co-expressed ErbB2 and Cre recombi-
nase, we demonstrated that while mammary epithelial
ablation of FAK delayed tumour onset and reduced the
number of neoplastic lesions, animals developed mam-
mary tumours with 100% penetrance. Collectively these
observations argue that while FAK contributes to ErbB2
tumour cell proliferation, it is ultimately dispensable for
ErbB2 mammary tumour initiation and progression.
Materials and methods
Transgenic mice
MMTV-Cre and GTRosa26 mice were described pre-
viously [18,19]. MMTV-NDL2-5, MMTV-NIC and FAK-
flox mice were generated and characterized as described
[12,20,21]. FAKflox mice were interbred with MMTV-
NDL2-5, MMTV-Cre and MMTV-NIC mice and rou-
tine genotyping was performed by PCR as described
[14]. Experimental and control virgin female mice were
monitored for mammary tumour formation by twice-
weekly palpation. All experiments involving mice were
conducted in accordance with McGill University Facility
Animal Care Committee guidelines which approves the
use of animals (mice) for research.
Tissue preparation, histology and b-galactosidase assay
wholemount analyses and the No. 3 thoracic glands for
histological analyses. Mammary gland wholemounts
were prepared as previously described [14]. For in situ
b-galactosidase assays, lungs were processed as
described previously [22]. For histological analyses,
mammary glands, tumour samples and lung lobes were
fixed in 10% neutral buffered formalin (Leica Microsys-
tems Inc., Concord, ON, Canada) and transferred to
70% ethanol the next day. Samples were then paraffin-
embedded, sectioned at 5 μm and H&E-stained. Quanti-
tative image analysis of the mammary gland whole-
mounts and H&E-stained sections was performed using
the Aperio ImageScope software (Vista, CA, USA). For
lung lobe examinations, five step sections were per-
formed at 50 μm intervals on lungs harvested from mice
bearing tumours for 8 weeks. Pulmonary metastases
were identified by microscopic analyses of H&E- or X-
gal-stained sections.
Immunostaining of tissue sections
For immunohistochemistry (IHC) and immunohisto-
fluorescence (IHF), tissue sections were deparaffinized in
xylene, endogenous peroxidase activity was blocked with
3% hydrogen peroxide in methanol, and antigen retrieval
was done in 10 mmol/L sodium citrate (pH 6) using a
pressure cooker (Cuisinart, Woodbridge, ON, Canada).
Sections were then blocked with Power Block Universal
Blocking Agent (Biogenex, Fremont, CA, USA), incu-
bated in primary antibody as described previously [14],
then incubated with biotinylated (Vector Laboratories,
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Burlington, ON, Canada) or Alexa Fluor 488 and 555
(Invitrogen/Life technology, Grand Island, NY, USA)-
conjugated secondary antibodies for IHC or IF, respec-
tively. Primary antibodies used for immunohistology
were Cre recombinase (PRB-106, Covance, Denver, PA,
USA), cleaved caspase-3 (9661, Cell Signaling, New Eng-
land Biolabs, Pickering, ON, Canada), Ki67 (NCL-L-
Ki67-MM1, NovoCastra, Leica Microsystems Inc.), and
FAK (05-537, Millipore, Billerica, MA, USA). For IHF
analysis, the slides were visualized using a Zeiss LSM 510
META confocal microscope (Carl Zeiss Canada, Toronto,
ON, Canada).
Immunoblotting and immunoprecipitations of tumour
tissue
Lysates were prepared from mammary tumour tissues
flash frozen in nitrogen, and immunoblots were per-
formed as described previously [20]. Antibodies used for
immunobloting analysis included Sigma (Oakville, ON,
Canada) b-actin (clone AC-15, A5441) and Pyk2 (P3902),
as well as Millipore phosphotyrosine (clone 4G10, 05-
321) and c-Src (clone GD11, 05-184). Neu (sc-284) and
CK8 (sc-101459) antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA, USA) and Paxillin (610051),
FAK (610087) and p130Cas (610271) were from BD Bios-
ciences (Mississauga, ON, Canada). Phospho-p130Cas
(4011), AKT (9272), phospho-AKT (9271), ERK1/2
(9102), phospho-ERK1/2 (9106), phospho-c-Src (2101),
and phospho-Paxillin (2541) antibodies were purchased
from Cell Signaling. All membranes were incubated with
horseradish peroxidase-conjugated secondary antibodies
(Jackson immunoresearch Laboratories, West Grove, PA,
USA) and visualized using enhanced chemiluminescence
(GE Healthcare Life Sciences, Baie d’Urfé, QC, Canada).
Immunoprecipitations of lysates from mammary tissues
were performed as described previously [20]. Pyk2 and
phospho-p130Cas were immunoprecipitated with the
same antibodies used for immunoblotting.
Primary cell culture, transfection and viral transduction
Tumours at 8 weeks post-palpation were processed
using a McIlwain tissue chopper (Mickle Laboratory
Engineering, Guildford, Surrey, UK), dissociated in col-
lagenase B/dispase II (Roche, Mississauga, ON, Canada)
for 2 hours at 37°C, washed with PBS + 1mM EDTA
and plated in DMEM supplemented with 2% FBS and
Mammary Epithelial Growth Supplement (MEGS - Invi-
trogen). pMSCV retroviral vector containing Cre recom-
binase or empty pMSCV vector were used for virus
production in 293VSV cells and subsequent transduc-
tions were carried out as previously described [23].
Transduced cell lines were selected and maintained in
DMEM + mammary epithelial growth supplement
(MEGS) with 2μg/ml puromycin (Sigma).
Proliferation, migration and invasion assays
CellTiter Aqueous MTS (Promega, Madison, WI, USA)
proliferation assays were performed according to the man-
ufacturer’s protocols using 2,500 cells per well in 96-well
optical bottom plates (Nalge Nunc International, Roche-
ster, NY, USA). For migration and invasion assays, cells
were seeded in serum-free medium in transwell chambers
(Falcon, BD Biosciences) with complete medium as a che-
moattractant, and for the invasion assay chambers were
coated with 5% matrigel (BD Biosciences). Cells were incu-
bated for 24 hours, formalin-fixed, and stained with crystal
violet. Cells that passed through the membrane were
visualized by microscopy and pixel counts were deter-
mined using ImageJ software.
Cell spreading assay
Cells of approximately 80% confluence were trypsinized,
washed in serum-free DMEM/0.5% BSA + MEGS con-
taining 100ug/ml soybean trypsin inhibitor (STI), and re-
suspended with serum-free DMEM/0.5% BSA + MEGS.
Suspension cells were seeded at 5 × 104 cells per well and
allowed to adhere for either 15 or 120 minutes at 37°C in
24-well plates coated with fibronectin (BD Biosciences,
#354411). At various time points, wells were washed
twice with PBS and adherent cells were fixed with 10%
neutral buffered formalin and then stained with crystal
violet (0.1%). After extensive washing to remove the free
dye, the stained cells were visualized by microscopy and
cell spreading was determined by counting at least
200 cells.
Mammary fat pad injection assay
Stable cell lines (2.5 × 105 cells in PBS) were injected into
the fourth inguinal mammary fat pad of athymic nude
mice (NCr; Taconic, Hudson, NY, USA). Mice were
monitored twice weekly for tumour formation by palpa-
tion. Tumour growth was assessed by weekly caliper
measurements.
Results
Mammary tumours that arise in conditional FAK mice
selectively retain FAK due to loss of Cre expression
To evaluate the role of FAK in ErbB2 mammary tumour
progression, we interbred mice carrying conditional FAK
alleles to separate transgenic strains carrying either
MMTV-Cre [18] or MMTV-activated ErbB2 (NDL 2-5)
[20]. We generated virgin female cohorts that carried one
or both conditional FAK alleles, MMTV-Cre and
MMTV-activated ErbB2 and monitored these mice for
the presence of palpable mammary tumours. In contrast
to the parental MMTV-activated ErbB2 strain and mice
harboring one conditional FAK allele, in which mammary
tumours occurred with an average onset of 200 days, ani-
mals carrying both FAK alleles developed mammary
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tumours with an average delayed onset of 232 days (Fig-
ure 1a). To determine whether this delay in tumour
onset was reflected in a decrease in the number of pre-
malignant lesions, we also performed wholemount ana-
lyses on adjacent mammary glands and scored the num-
ber of hyperplasia. The results showed that tumour-
bearing mice homozygous for the floxed FAK alleles pos-
sessed fewer lesions than wild-type or heterozygous mice
(Figure 1c and 1d). Quantitative analyses of mammary
glands from 6-month-old non-tumour-bearing animals
demonstrated that disruption of both FAK alleles
resulted in a significant decrease in the area of fat pad
occupied by hyperplastic lesions (Figure 1b). Taken
together, these observations indicate that mammary
epithelial disruption of FAK results in a dramatic reduc-
tion in ErbB2-induced tumours.
One possible explanation for the eventual induction of
mammary tumours in FAKflx/flx mice is that they are
derived from a population of mammary epithelial cells
that failed to express Cre recombinase. In fact the mam-
mary tumours that eventually arose in PyVmT mice
with either conditional b1 integrin alleles or conditional
FAK alleles were identified as escapee populations of
epithelial cells. Indeed, these cells failed to express Cre
recombinase due to the stochastic nature of Cre expres-
sion in MMTV-Cre transgenic strains [14,22]. To test
this possibility, we performed immunoblot analyses with
FAK- and ErbB2-specific antisera on lysates from either
parental MMTV-NDL2-5 tumours or tumours homozy-
gous for the FAK conditional alleles. The results showed
that tumours derived from both genotypic combinations
expressed elevated levels of FAK and ErbB2 (Figure 2a).
To evaluate whether retention of FAK protein was due
to loss of Cre expression, we also performed immuno-
histochemical analyses on tumour sections from these
genotypes with FAK- and Cre-specific antisera. Consis-
tent with elevated FAK expression observed in the
immunoblot analyses, tumour epithelia bearing both
FAK conditional alleles failed to express Cre recombi-
nase (Figure 2b). The inability to detect Cre recombinase
in these sections was not due to the sensitivity of the anti-
body reagent as abundant Cre expression could be
detected in adjacent normal epithelial cells (Figure 2b, see
arrows). These data argue that the majority of mammary
tumours that arise in this cross derive from escapee mam-
mary epithelial cells that fail to express Cre recombinase.
Although the majority of tumours carrying both FAK
null alleles were proficient for FAK expression due to the
lack of Cre expression, several neoplastic glands pos-
sessed areas of epithelial cells that maintained Cre
expression (Figure 2c) and therefore lost FAK expression
(Figure S1a in Additional file 1). We evaluated both the
proliferative and apoptotic status of these FAK-deficient
hyperplastic lesions by immunostaining sections with
antibodies directed against the Ki67 proliferation marker
and the cleaved caspase 3 apoptotic marker. While Cre-
positive mammary epithelia lacking functional FAK
(Figure S1a in Additional file 1) exhibited low levels of
apoptotic cell death as comparable to wild-type cells
(Figure S1b and S1c in Additional file 1), they possessed
a significantly reduced proliferative capacity (Figure 2c
and 2d). Collectively these data indicate that FAK-ablated
ErbB2 tumour cells are at a proliferative disadvantage
relative to their FAK-expressing counterparts.
Another important feature of the activated ErbB2
mammary tumour mouse model is that 60% of tumour-
bearing animals will develop metastatic lesions to the
lung [20]. To determine if the metastatic phase of ErbB2-
induced tumour progression is affected by FAK deletion,
we subjected the lungs from tumour-bearing mice to his-
tological analyses. The tumour-bearing FAKflx/flx mice
developed lung metastases in the same proportion as the
parental MMTV-activated ErbB2 strain (Figure 3a) with
similar numbers of metastatic lesions (Figure 3b). Given
that a large percentage of mammary tumours that devel-
oped in this strain were FAK-proficient due to escape
from Cre-mediated recombination, it was possible that
these metastatic lesions derived from escapee tumours.
To test this idea, we introduced a Cre-inducible b-galac-
tosidase reporter gene (GTRosa26 strain) [19], and
counted the number of X-gal-positive lesions in lungs
from either wild-type animals or mice bearing both con-
ditional FAK alleles. Although the majority of metastatic
lesions derived from MMTV-activated ErbB2 mice had
undergone Cre-mediated expression of the b-galactosi-
dase reporter, none of the metastatic lesions detected in
FAKflx/flx mice bearing both FAK conditional alleles were
positive for X-gal, indicating that they originated from
FAK-proficient escapee populations (Figure 3c and 3d).
Again, these observations reinforce the concept that loss
of FAK in ErbB2 tumour cells renders them at a competi-
tive disadvantage in their capacity to colonize the meta-
static site.
Acute loss of FAK in established ErbB2 tumour cells
impacts on their proliferative ability
Although the above studies indicated that FAK plays a cri-
tical role in the transition from neoplasia to full adenocar-
cinoma during ErbB2 tumour progression, whether FAK
is required in established ErbB2 mammary tumour cells
remained unclear. To test this possibility, we explanted
two independent cell lines from the parental MMTV-
NDL2-5 tumours and from ErbB2 induced tumours carry-
ing both conditional FAK alleles (NDL2-5/FAKflx/flx) and
infected them with empty vector controls or retroviral vec-
tors expressing Cre recombinase (Figure 4). Immunoblot
analyses with FAK-specific antisera of cell lysates from
FAKflx/flx cell lines revealed that FAK expression was lost
Lahlou et al. Breast Cancer Research 2012, 14:R36
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Figure 1 Ablation of focal adhesion kinase (FAK) expression increases the latency of mammary tumour formation and results in fewer
hyperplastic lesions in mouse mammary tumour virus (MMTV)-Cre/-NDL2-5 mice. (a) Kinetics of mammary tumour onset in FAKwt/wt,
FAKflox/wt, and FAKflox/flox/MMTV-Cre/-NDL2-5 virgin female mice. The age indicated is that at which a mammary tumour is first palpable in each
transgenic strain. T50 denotes the age at which a tumour is palpated in 50% of the mice. *P < 0.001 vs. FAK
wt/wt mice, Student’s t-test.
(b) Quantification of the area occupied by hyperplastic lesions expressed as a percentage (± standard error of the mean, SEM) of the total
mammary gland surface (c). Quantitative image analysis of the mammary gland wholemounts was performed using the Aperio ImageScope
software. P < 0.05 vs. FAKwt/wt mice, Student’s t-test. (c) Representative fourth inguinal mammary gland wholemounts excised from late-stage
tumour-bearing animals that are FAKwt/wt (left), FAKflox/wt (center) and FAKflox/flox (right)/MMTV-Cre/-NDL2-5. Scale bar: 5 mm. (d) H&E-stained
sections of mammary glands from 6-month-old non-tumour-bearing animals that are FAKwt/wt (left), FAKflox/wt (center) and FAKflox/flox (right)/
MMTV-Cre/-NDL2-5. Images are representative of at least five animals from each genotype and multiple fields were quantified. Scale bars:
200 μm.
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upon infection with retroviral Cre vector, demonstrating
efficient deletion of FAK (Figure 4a). In addition to FAK
protein levels, we also evaluated the phosphorylation sta-
tus of the FAK binding partners p130Cas, Paxillin and
c-Src in these cells. Concomitant with abolition of FAK
protein, we noted a significant reduction in the levels of
phosphorylated c-Src, Paxillin and p130Cas (Figure 4a).
Consistent with reduction in c-Src activation and
p130Cas-initiated signaling, the FAK-deficient ErbB2
tumour cells exhibited a proliferative defect relative to
Figure 2 Focal adhesion kinase (FAK)-negative mammary epithelial neoplastic cells show a reduced proliferative capacity. (a) FAK and
Neu expression in FAKwt/wt (left) and FAKflox/flox (right)/mouse mammary tumour virus (MMTV)-Cre/-NDL2-5 end-stage mammary tumours was
determined by immunoblotting. Cytokeratin 8 (CK8) was used as a control for epithelial content. b-actin was used as a loading control. (b)
Immunohistochemistry analyses of Cre (left) and FAK (right) expression on paraffin sections of end-stage mammary tumours from FAKwt/wt (upper)
and FAKflox/flox (lower)/MMTV-Cre/-NDL2-5 animals. Data are representative of at least five animals from each genotype. FAK is co-expressed with
Cre throughout the MMTV-Cre/-NDL2-5-derived solid tumour tissue. In FAKflox/flox tumour sections, Cre-positive/FAK-negative cells are detectable
only in small hyperplastic or non-transformed ductal structures. (Scale bars: 100 μm). (c) Paraffin sections of hyperplastic mammary glands from
6-month-old FAKwt/wt and FAKflox/flox/MMTV-Cre/-NDL2-5 mice were submitted to immunohistofluorescence analyses of Cre and Ki67 expression.
(Scale bars: 20 μm). (d) Graphical representation of the immunostaining shown in (c). Percentages (± standard error of the mean, SEM) were
calculated after counting multiple fields from at least five animals from each genotype. P <0.01 vs. FAKwt/wt mice, Student’s t-test.
Lahlou et al. Breast Cancer Research 2012, 14:R36
http://breast-cancer-research.com/content/14/1/R36
Page 6 of 14
ba
n=12
n=8 n=10
wt/wt flx/flxflx/wtFAK:
0
1
2
3
# 
of
 
m
e
ta
st
at
ic
 fo
ci
 / 
lu
ng
 lo
be
(pe
r m
et
.
+
ve
 a
ni
m
al
)
Lung Lesions
MMTV-Cre/-NDL2-5
c
/ FAKwt/wt
/ FAKflx/flx
d
MMTV-Cre/-NDL2-5; Rosa26
%
 o
f m
ice
 w
ith
 lu
ng
 m
e
ta
st
as
es
Lung Metastasis
MMTV-Cre/-NDL2-5
0
20
40
60
80
wt/wt flx/flxflx/wtFAK:
n=19
n=14 n=19
MMTV-Cre/-NDL2-5
0
20
40
60
80
wt/wt flx/flxFAK:
n=7
n=8
%
 o
f R
os
a
26
 m
ic
e
w
ith
 lu
ng
 m
e
ta
st
as
e
s
% of lungs with 
X-Gal-stained metastases
75%
0%
Figure 3 Focal adhesion kinase (FAK)-deleted cells do not contribute to lung metastasis in the mouse mammary tumour virus
(MMTV)-Cre/NDL2-5 mouse model. (a) Bar graphs indicate the percentage of lung metastases for FAKwt/wt, FAKflox/wt and FAKflox/flox/MMTV-
Cre/-NDL2-5 mice and in (b) the average number of metastatic foci per lung lobe. Error bars represent the standard error of the mean (SEM).
No statistically significant differences were observed (unpaired Student t-test). (c) Representative sections of X-gal-stained lung lobes from FAKwt/
wt (left) (n = 7) and FAKflox/flox (right) (n = 8)/MMTV-Cre/NDL2-5/GTRosa26 mice bearing late-stage tumours. Arrows (lower) indicate lung lesions
lacking positive X-gal staining. Scale bars: 500 μm. (d) Bar graphs indicate the percentage of X-gal-positive lung metastases in FAKwt/wt (75% of
metastases, n = 7) and FAKflox/flox/MMTV-Cre/-NDL2-5 mice (0% of metastases, n = 8).
Lahlou et al. Breast Cancer Research 2012, 14:R36
http://breast-cancer-research.com/content/14/1/R36
Page 7 of 14
their FAK-proficient counterparts (Figure S2a in Addi-
tional file 2). The FAK-deleted ErbB2 tumour cells also
showed impairment in migration, invasion and spreading
compared to control cells (Figure S2b in Additional file 2
and Figure S3 in Additional file 3). Collectively these
observations indicate that loss of FAK in established
ErbB2 tumour cells impacts on a combination of cell pro-
liferation, migration, invasion and spreading.
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Figure 4 Focal adhesion kinase (FAK) deletion in established ErbB2 tumour cells results in impaired tumour growth. (a) FAK ablation in
NDL2-5 cell lines decreases phosphorylation of p130Cas, Paxillin and c-Src. Cell lines derived from FAKwt/wt (left side, 1438 and 5847) and FAKflox/
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for the indicated proteins. (b) NDL2-5/FAKwt/wt cell lines expressing Cre and NDL2-5/FAKflx/flx cell lines expressing empty (vector) or Cre vector
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To evaluate whether these FAK-null tumour cells were
also compromised in their capacity to form mammary
tumours, we transplanted them into the cleared fat pads of
immunodeficient mice and monitored tumour growth. In
contrast to FAK-expressing cells that formed measurable
tumours by 3 to 4 weeks post-transplantation, the FAK-
deficient cells formed tumours of comparable size only
after 5 to 6 weeks (Figure 4b). Interestingly, immunoblot
analyses with FAK-specific antibodies of tumour lysates
from the transplanted FAK-deficient cells revealed the pre-
sence of FAK protein, which may reflect either stromal cell
FAK levels or selective expansion of the small number of
tumour cells that had not undergone Cre-mediated exci-
sion in the initial transplant (Figure S2c in Additional
file 2). Taken together, these observations provide further
evidence that retention of FAK signalling provides a pro-
found proliferative advantage to ErbB2-driven tumour
cells.
FAK is dispensable for the initiation phase of ErbB2-
induced mammary tumour progression
While the above studies provide compelling evidence that
FAK contributes to ErbB2 mammary tumour progression,
one limitation of this approach is that 30% of the mam-
mary epithelial cells do not express the Cre transgene [14].
If the targeted signaling molecule is critical for tumour
development, this escapee population will selectively con-
tribute to the emerging tumour [22]. To prevent this esca-
pee population from interfering with our analyses, we have
recently developed transgenic mice that co-express both
the activated form of ErbB-2 and Cre recombinase under
the transcriptional control of the MMTV promoter
(MMTV-NIC strain) [21]. Due to the presence of an inter-
nal ribosome entry site (IRES) between activated ErbB2
and Cre, translation of these two proteins are directly
coupled from the same polycistronic mRNA. Using this
unique transgenic strain, we generated cohorts of virgin
female mice carrying either one or both FAK conditional
alleles (Figure 5). Consistent with our previous cross with
the MMTV-NDL2-5 strain, MMTV-NIC animals homo-
zygous for both conditional FAK alleles exhibited a signifi-
cant delay in tumour onset (Figure 5a) that was further
associated with a deficit in the number of pre-malignant
lesions in the adjacent mammary glands of tumour-bear-
ing mice (Figure 5c and 5e) as well as in 4-month-old
tumour-free mice (Figure 5d and 5f). However, once
tumours developed in all of the animals, they grew to simi-
lar volumes to their parental controls (Figure 5b).
To confirm that both conditional FAK alleles were
deleted in tumour samples, we subjected tumour lysates
to immunoblot analyses with FAK-specific antisera. FAK
levels observed in tumours harbouring both conditional
FAK alleles expressed dramatically reduced levels of FAK
(Figure 6a). We confirmed that this basal level of FAK
protein levels was due to the adjacent stroma by subject-
ing tumour sections to immunohistochemical analyses
with both Cre- and FAK-specific antisera (Figure 6b).
The ablation of FAK function was further accompanied
by reduced total Paxillin protein and reduced (but not
lost) tyrosine phosphorylation of FAK substrates such as
p130Cas and Paxillin (Figure S4 in Additional file 4).
However c-Src, ERK and AKT activation were not
affected by FAK deletion (Figure S4 in Additional file 4).
Given that the ErbB2 tumour epithelia were comple-
tely devoid of FAK protein (Figure 6b), we next evalu-
ated whether these FAK-deficient tumours were capable
of forming metastatic lesions within the lung. Surpris-
ingly, histological analyses of lung lobes from tumour-
bearing females revealed that both the penetrance and
number of metastatic lesions were not significantly
impacted (Figure 6c and 6d).
One hypothesis for the lack of a defect in both tumour
growth and metastasis is that the closely related Pyk2
kinase is functionally substituting for FAK. Indeed, func-
tional compensation of FAK ablation by Pyk2 has pre-
viously been reported in mice lacking endothelial cell
FAK [24]. Recently, a compensatory role for Pyk2 in the
promotion of FAK-null mammary cancer stem cell
tumourigenicity and metastatic activity has been shown
in the context of the PyVmT oncogene [25]. To evaluate
whether Pyk2 could be detected in FAK-null tumours,
we measured Pyk2 levels and activity by immunoblot/
immunopreciptation analyses with Pyk2 and phosphotyr-
osine-specific antisera (Figure S5 in Additional file 5).
Although no difference in the levels of Pyk2 expression
was observed in FAK-deficient tumours (Figure S5a and
S5b in Additional file 5), Pyk2 is overexpressed in ErbB2
tumours when compared to adjacent mammary tissue
that does not express high levels of activated Erbb2 (Fig-
ure S5c in Additional file 5). Loss of FAK overexpression
in tumours bearing both conditional FAK alleles did not
affect ErbB2-induced Pyk2 overexpression (Figure S5c in
Additional file 5). Consistently, no significant difference
in the levels of Pyk2 tyrosine phosphorylation was noted
when comparing FAK-null tumours to controls (Figure
S5d in Additional file 5). Interestingly, Pyk2 could still
co-immunoprecipitate with p130Cas in FAK-ablated
tumour lysates (Figure S5d in Additional file 5), suggest-
ing that the remaining levels of p130Cas phosphorylation
were due to the ability of Pyk2 to functionally substitute
for FAK.
Discussion
Elevated expression of FAK has been previously impli-
cated as an important determinant in both the initia-
tion and the progression of ErbB2-positive breast
cancers [6,7]. Consistent with these observations, sev-
eral in vitro studies with ErbB2-transformed mammary
Lahlou et al. Breast Cancer Research 2012, 14:R36
http://breast-cancer-research.com/content/14/1/R36
Page 9 of 14
Age (days)
%
 T
u
m
o
u
r-
Fr
ee
 
An
im
a
ls
0
20
40
60
80
100
0 50 100 150 200 250 300 350 400
FAKwt/wt
T50 = 146d (n=23)
FAKflx/wt
T50 = 145d (n=22)
FAKflx/flx
T50 = 182d (n=21)
*
MMTV-NIC Tumour Onset
d MMTV-NIC
a
2
4
6
8
b
To
ta
l T
u
m
o
r 
Vo
lu
m
e
 
(cm
3 )
0
n=10 n=11
wt/wt flx/flxflx/wtFAK:
Tumour Burden
n=11
MMTV-NIC
LN
/FAKwt/wt
LN
/FAKflx/flx
200
400
600
800
1000
1200
f
Ep
ith
el
ia
l c
o
n
te
nt
 p
er
 
m
a
m
m
a
ry
 
gl
a
n
d 
se
ct
io
n 
(ce
lls/
m
m
2 )
0
n=5
n=6
wt/wt flx/flxFAK:
MMTV-NIC
p<0.05
/FAKwt/wt
c
/FAKflx/flx
e
wt/wt flx/flxFAK:
Ar
ea
 o
cc
up
ie
d 
by
 
vi
si
bl
e
 le
si
on
s
(%
 of
 
to
ta
l m
a
m
m
a
ry
 
gl
a
n
d)
0
2
4
6
8
n=10
n=12
MMTV-NIC
10
p<0.05
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Error bars represent standard error of the mean (SEM). (c) Representative fourth inguinal mammary gland wholemounts excised from late-stage
tumour-bearing animals from FAKwt/wt (left) and FAKflox/flox (right)/MMTV-NIC. LN indicates the lymph node. (d) H&E-stained sections from mammary
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tumour cells have identified FAK and its closely related
family member Pyk2 as critical signals in ErbB2-depen-
dent proliferation [8,9,17]. Although these studies pro-
vide compelling data supporting a role for FAK in
ErbB2 tumour progression, whether FAK is required in
vivo for ErbB2 mammary tumour progression has not
been addressed; this question is imperative given that
the integrin/FAK signalling output from ErbB2 tumour
cells is highly dependent on the microenvironment
within the mammary fat pad. Here we demonstrate
using two well-characterized transgenic mouse models
of ErbB2 breast cancer that while the presence of func-
tional FAK confers a proliferative advantage to ErbB2
tumour cells, metastatic ErbB2 mammary tumours can
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be generated in the complete absence of FAK
expression.
To evaluate the role of FAK in ErbB2 mammary
tumour progression, we initially interbred the MMTV-
activated ErbB2 strain (NDL2-5) [20] with separate
strains of mice bearing MMTV-Cre and conditional FAK
alleles [12,18]. Although a delay in mammary tumour
onset was observed (Figure 1), the majority of tumour
epithelia maintained expression of FAK due to loss of
Cre expression (Figure 2). This phenomenon persisted
throughout the progression to metastasis since we could
not detect any FAK-deficient lesions in the lungs of
FAKflx/flx tumour-bearing mice (Figure 3). One potential
explanation for the presence of these escapee populations
of tumour cells that have not undergone Cre-mediated
recombination is that the few FAK-ablated tumour
epithelia detected were at a proliferative disadvantage
relative to their FAK-proficient counterparts (Figure 2).
This observation is consistent with results from similar
experiments in the PyVmT tumour model system where
FAK was shown to influence the proliferative status of
these tumour cells [14,16,17]. Likewise, mammary dis-
ruption of b1-integrin or c-Src signalling pathways
(which are immediately upstream of FAK) also impairs
PyVmT tumour cell proliferation [22,23]. Collectively
these data argue that the integrin/c-Src/FAK signalling
network is a key regulator of the proliferative capacity of
both ErbB2 and PyVmT mammary tumour cells.
While these studies indicate the importance of FAK in
the initiation phase of ErbB2 mammary tumour progres-
sion, acute deletion of FAK in established tumour cells
also impacts on their ability to proliferate in both in vitro
and in vivo settings (Figure 4) (Figure S2a in Additional
file 2). In fact, from a population of tumour cells that
were largely FAK-deficient (Figure 4a), the tumours that
eventually arose regained FAK expression (Figure S2c in
Additional file 2). The presence of FAK protein suggests
that these tumour cells presumably derived from the
small population of cells that had not undergone produc-
tive excision of the FAK conditional allele; alternatively,
it could also represent FAK from the stromal compart-
ment of the mammary gland which was the case in the
FAK-null/MMTV-NIC tumours (Figure 6a and 6b).
Again these data suggest that retention of a functional
FAK gene confers a strong proliferative advantage to
ErbB2 tumour cells over their FAK-deleted counterparts.
Although these data demonstrate that FAK activation is
involved in the induction and maintenance of ErbB2
tumours, our studies with the MMTV-NIC model indi-
cate that ErbB2 tumours completely lacking FAK can
develop eventually. By contrast, deletion of FAK in the
PyVmT model prevented tumour progression entirely
[14]. One possible explanation for this difference is that
the tumour-initiating cell population in the PyVmT
model is absolutely reliant on FAK, whereas this popula-
tion in the ErbB2 model can function independently of
FAK signalling. Consistent with this hypothesis, FAK
function has been reported to be important in tumour-
initiating cells in the PyVmT model [15].
Examination of downstream signaling pathways
revealed that loss of FAK resulted in a reduction in tyr-
osine phosphorylation of p130Cas (Figure 6). However,
in contrast to complete loss of tyrosine phosphorylation
of p130Cas in an ErB2 model with abrogation of either
b1-integrin or integrin linked kinase (ILK) [26,27], FAK-
deficient tumours still retained a basal level of tyrosine-
phosphorylated p130Cas that was further correlated
with its ability to couple with the FAK-related kinase
Pyk2 (Figure S4 in Additional file 4 and Figure S5d in
Additional file 5). Although it has been proposed that
FAK was critical for migratory behaviour whereas Pyk2
was involved in the proliferative phase of ErbB2 tumour
induction in vitro [8], the observation that FAK-null
ErbB2 tumours can form metastatic lesions argues that
at least in the in vivo setting, Pyk2 can functionally sub-
stitute for FAK. One of the main targets for Pyk2 is
likely p130Cas, as it has been reported that p130Cas is
essential for ErbB2 tumour progression [28]. While
these data implicate the Pyk2/FAK/p130Cas signalling
complex as an important signalling element in ErbB2
tumour progression, both ILK- and b-1 integrin-ablated
ErbB2 tumours lack detectable tyrosine phosphorylated
p130Cas [26,27] indicating that tyrosine phosphorylation
of the p130Cas scaffold is not essential for ErbB2
tumour induction. However, tumours from both these
models are poorly metastatic [26,27] suggesting that
engagement of Pyk2/FAK/p130Cas signalling likely plays
a more important role in the metastatic phase of ErbB2
tumour induction. Consistent with this concept, upregu-
lation of Pyk2 has been observed in metastatic foci
derived from PyVmT cancer stem cells devoid of FAK
function [25].
One of the most interesting findings of these studies
was the observation that acute knockout of FAK from
established ErbB2 tumour cells (Figure 4) was more dele-
terious than early abrogation of FAK function in the
MMTV-NIC model (Figure 6). A hypothesis for this dif-
ference in response between these two models is that
established ErbB2 tumour cells have become addicted to
the requirement for FAK function whereas MMTV-NIC-
initiated tumour cells have evolved to circumvent the
FAK signalling network through compensation by Pyk2.
Indeed, the phenomenon of oncogene addiction has been
observed in a number of human cancers [29].
Conclusions
Collectively these observations suggest that targeting both
Pyk2 and FAK will be required to effectively eliminate
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ErbB2-dependent mammary tumours. Indeed, it has been
reported that small molecule inhibitors specific to FAK
tyrosine kinases have both in vitro and in vivo efficacy in
interfering with mammary tumour progression [30,31].
PF-562-271, a dual FAK/Pyk2 inhibitor with anti-tumour
activity, has been successfully used in preclinical studies
[25,32]. The future clinical application of therapeutic stra-
tegies against FAK/Pyk2 signalling has great potential for
the treatment of primary human breast cancer.
Additional material
Additional file 1: Figure showing that focal adhesion kinase (FAK)-
negative mammary epithelial neoplastic cells do not exhibit an
increase in apoptosis. (a) Paraffin sections of hyperplastic mammary
glands from 6-month-old FAKwt/wt and FAKflox/flox/mouse mammary
tumour virus (MMTV)-Cre/-NDL2-5 mice were submitted to
immunofluorescence analyses with Cre- and FAK-specific antibodies.
Note that Cre-positive cells in lesions from FAKflox/flox/MMTV-Cre/-NDL2-
5 mice are FAK-negative. (b) Paraffin sections of hyperplastic mammary
glands from 6-month-old FAKwt/wt and FAKflox/flox/MMTV-Cre/-NDL2-5
mice were submitted to immunofluorescence analyses of Cre and
cleaved caspase-3 expression. Scale bars: 20 μm. (c) Graphical
representation of the immunostaining shown in (b). Percentages (±
standard error of the mean) were calculated after counting multiple
fields from at least five animals from each genotype.
Additional file 2: Figure showing that focal adhesion kinase (FAK)-
deficient tumour cells exhibit proliferative, migratory and invasive
defects. (a) FAK ablation in NDL2-5 tumour cells decreases proliferation.
MTS proliferation assays (n = 3) were performed on NDL2-5/FAKwt/wt
and NDL2-5/FAKflx/flx cell lines expressing empty vector (vector) or Cre
vector (Cre). Data are normalized to values at 24 hours for the control
cells. Error bars represent standard error of the mean (SEM). P < 0.01, vs.
empty vector control (unpaired Student’s t-test). (b) Migration and
invasion through matrigel was assayed in NDL2-5/FAKwt/wt and NDL2-5/
FAKflx/flx cell lines expressing empty vector (vector) or Cre vector (Cre).
Pixel count analyses of crystal violet-stained membranes were performed
on five different fields for each cell line (n = 3). Error bars represent SEM.
(c) Tumour lysates from FAK-deficient and -proficient NDL2-5 cell lines
injected into the cleared fat pads of immunodeficient mice were
immunoblotted with the indicated antibodies. b-actin was used as
loading control.
Additional file 3: Figure showing that focal adhesion kinase (FAK)-
deficient tumour cells exhibit a cell spreading defect. (a)
Quantification of cell spreading shown in (b) by counting the number of
spread cells (marked by arrows in b) among at least 200 cells in NDL2-5/
FAKwt/wt and NDL2-5/FAKflx/flx cell lines expressing empty vector
(vector) or Cre vector (Cre). The percentage of spread cells (that is, cells
that had become flattened) in five microscopic fields was determined.
Cells were fixed for either 15 or 120 minutes after plating on fibronectin-
coated slides and then stained with crystal violet. Error bars represent
SEM. (b) Representative image of cell spreading after 120 minutes. Scale
bars: 5 mm.
Additional file 4: Figure showing that focal adhesion kinase (FAK)-
ablated tumours show reduced levels of tyrosine phosphorylated
p130Cas and Paxillin. (a) Lysates from FAKwt/wt and FAKflx/flx/MMTV-
NIC end-stage mammary tumours were immunoblotted for the indicated
proteins. Data are from 10 animals of each genotype. b-actin was used
as loading control. (b) Quantification using ImageJ software of the
immunoblots shown in (a) for total p130Cas and Paxillin, normalized to
cytokeratin 8 (CK8) (control for epithelial content). P < 0.05 vs. FAKwt/wt
mice, Student’s t-test. (c) Quantification using ImageJ software of
phosphorylation levels for the indicated proteins relative to total protein
from the immunoblots shown in (a), normalized to CK8 (control for
epithelial content). P < 0.05 vs. FAKwt/wt mice, Student’s t-test.
Additional file 5: Figure showing that S5 Pyk2 is still overexpressed
and associated with p130Cas in focal adhesion kinase (FAK)-deleted
tumours. (a) Pyk2 expression was determined by immunoblotting tumour
lysates from FAKwt/wt and FAKflx/flx mouse mammary tumour virus
(MMTV)-NIC tumours. b-actin was used as a loading control. Data are
representative of at least 10 animals of each genotype. (b) Quantification
using ImageJ software of the immunoblots shown in (a) for total Pyk2
expression, normalized to b-actin. (c) Pyk2 and ErbB2 expression in both
adjacent and tumour epithelia was evaluated by immunoblot analyses
with Pyk2- and ErbB2-specific antisera. b-actin was used as a loading
control. (d) Upper: lysates from FAKwt/wt and FAKflx/flx/MMTV-NIC end-
stage mammary tumours were immunoprecipitated with anti-Pyk2 (left)
and anti-p130Cas (right) antibodies (n = 3). Immunoprecipitates were
immunobloted with phosphotyrosine, Pyk2 and p130Cas antibodies.
Lower: the bar graphs show Pyk2 phosphorylation relative to levels in
FAKwt/wt from the immunoprecipitation with anti-Pyk2 (left) and Pyk2
interaction with p130Cas relative to levels in FAKwt/wt from the
immunoprecipitation with anti-p130Cas (right). No significant differences
were observed (unpaired Student t-test).
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